Idarubicin pdf

April 1, 2005 - March 31, 2006 April 1, 2006 March 31, 2007 1. Outline of pension plan: 1. Outline of pension plan: The Parent Company: The Parent Company: The Parent Company adopts defined-benefit Same as the left. pension plan and retirement lump-sum payments. The transfer rate to the defined-benefit pension plan fund is 45%. Additional severance payment may be made to some employees. Consolidated subsidiaries: Consolidated subsidiaries: Certain Japanese subsidiaries adopt a Same as the left. defined-benefit pension type of a joint pension plan, an approved pension scheme and retirement lump-sum payments. Certain overseas subsidiaries adopt a defined contribution plan as well as a defined-benefit plan. Additional severance payment may be made to some employees. 2. Projected benefit obligation benefits at March 2. Projected benefit obligation benefits at March 31, 2006 31, Millions of Yen ; Millions of Yen ; Projected benefit obligation 113, 096 ; Projected benefit obligation 113, 860 ; Fair value of plan assets 103, 610 Fair value of plan assets 102, 588 Net unfunded obligation 9, 485 ; Net unfunded obligation 11, 271 ; Unrecognized actuarial gain 14, 284 ; Unrecognized actuarial gain 11, 347 ; Unrecognized prior service cost Note 1 ; Unrecognized prior service cost Note 1 ; 11, 808 ; 9, 149 ; Liability for retirement benefits 35, 577 ; Liability for retirement benefits 31, 768 ; Notes: Notes: Note 1 ; Reflects the changes of relevant Note 1 ; Reflects the changes of relevant regulation including the changes in guarantee regulation including the changes in guarantee period in October 2005 and the elimination of period in October 2005 and the elimination of additional benefit on December 1, 2004. additional benefit on December 1, 2004. Note 2 ; Certain subsidiaries adopt the simple Note 2 ; Certain subsidiaries adopt the simple method to calculate projected benefit obligation. method to calculate projected benefit obligation. 3. Components of the retirement benefit costs: 3. Components of the retirement benefit costs: Millions of Yen ; Millions of Yen ; Service cost Note 1 ; 4, Service cost Note 1 ; 3, 867 Interest cost 2, 900 Interest cost 2, 723 Expected return on plan assets 2, 651 ; Expected return on plan assets 3, 380 ; Amortization of unrecognized net actuarial loss Amortization of unrecognized net actuarial loss 6, 473 423 Amortization of prior service cost Note 2 ; Amortization of prior service cost Note 2 ; 2, 893 ; 2, 643 ; Contribution to defined contribution plan and Contribution to defined contribution plan and 950 1, 314 others others Retirement benefit costs 8, 784 Retirement benefit costs 2, 306 Notes: Notes: Note 1 ; All retirement benefit costs of subsidiaries Note 1 ; All retirement benefit costs of subsidiaries utilizing the simple method are included in utilizing the simple method are included in Service cost. Service cost.
LURIAN HOMEWORLD The Lurian homeworld, Hainault VI, is a cold rock in space, and the only farmable area is along the equator. Surviving such a homeworld has made the Lurians a very hard race. LURIAN SOCIETY AND CULTURE The Lurian homeworld is a difficult place to live, and many rely on their Ferengi neighbors to take them offworld, exchanging cheap labor for a better life. The Lurians have made no decision on whether to apply for Federation membership, as they see their only chance to survive in their willingness to serve many masters offworld. Food is a large part of the lurian culture, and those who prepare food are given great respect. Lurians eat four large meals each day.

In the safety analysis, including analysis of adverse events, infections, and premature withdrawal from the study. Standard laboratory tests, including hematologic analysis, analysis of serum chemistry, and urinalysis profiles were performed at screening, at base line, and at weeks 12 and 24. Adverse events and abnormal laboratory values were graded on a scale derived from the Common Toxicity Criteria of the National Cancer Institute. Serum samples obtained at base line and week 24 were tested for antibody to etanercept with the use of an enzyme-linked immunosorbent assay ELISA ; .16 Samples that were positive on ELISA were tested for neutralizing antibodies with the use of a binding assay.

Idarubicin and ara-c are both designed to insert themselves into dna the genetic material of cells ; and to stop dna from repairing itself 1.1 The term vitamin A should be used as the generic descriptor for all 3-ionone derivatives, other than provitamin A carotenoids, exhibiting qualitatively the biologi cal activity of ail-trans retinol. Thus, phrases such as "vitamin A activity, " "vita min A deficiency, " and "vitamin A in the form of represent preferred usage and ifex. Kimmins, S. and MacRae, T.H. 2000 ; Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins. Cell Stress & Chaperones 5, 76-86.

Hydroxyurea Hydroxyzine HCl Hydroxyzine Pamoate Hyoscyamine Sulfate Hypromellose Phthalate Formerly Cat. No. 33010-7 ; Ibuprofen Idarubicin HCl Idoxuridine Ifosfamide Imidazole Limit test Imidurea Iminodibenzyl Limit test Imipenem Monohydrate Imipramine HCl Indapamide Indigotindisulfonate Sodium Indocyanine Green Indomethacin Insulin Insulin Human each mg is equal to 26.4 USP Human Insulin Units on the as is basis ; Insulin Beef ; Insulin Pork ; Iocetamic Acid Iodipamide o-Iodohippuric Acid Iodoquinol Iohexol Iohexol Related Compound A Limit test Iohexol Related Compound B Limit test Iohexol Related Compound C Iopamidol Iopamidol Related Compound A Limit test Formerly Cat. No. 07480-1 ; Iopamidol Related Compound B Limit test Iothalamic Acid Ipodate Calcium Ipodate Sodium Isocarboxazid Isoetharine HCl Isoflurane L-Isoleucine Isomalathion Limit test Isoniazid Isopropamide Iodide Isopropyl Myristate Isopropyl Palmitate Isoproterenol HCl Isosorbide 75% solution ; Diluted Isosorbide Dinitrate 25% mixture with mannitol ; Isotretinoin Isoxsuprine HCl Isradipine Isradipine Related Compound A Kanamycin Sulfate Ketamine HCl Controlled Substance CIII Ketoconazole Ketoprofen Ketoprofen Related Compound A Limit test Ketorolac Tromethamine Labetalol HCl Anhydrous Lactose Lactose Monohydrate and ifosfamide.

Clinical studies four prospective randomized studies, three and one italian, have been conducted to compare the efficacy and safety of idarubicin idr ; to that of daunorubicin dnr ; , each in combination with cytarabine as induction therapy in previously untreated adult patients with acute myeloid leukemia aml and iloprost.
Ms. Sharon Foote Mr. Miguel Forbes Mrs. Magdalena Forhans Mr. Angelo Forlenza Ms. Linda P. Fosler Mrs. Jane A. Foster Mr. and Mrs. Byron M. Fox Mr. and Mrs. Myron J. Fox Mr. Robert D. Frandsen Ms. Debra Frank R & H Frank Family Foundation Mr. and Mrs. James A. Frank Frank Visceglia Foundation Mr. and Mrs. Wayne C. Frankenfield Ms. Sara Franks Mr. and Mrs. Warren B. Frazer Mr. and Mrs. James Freasier Mr. and Ms. Arthur Fredston Mr. Robert Freeberg Ms. Denna Freeburg Dr. and Mrs. Robert Freedman Mr. Bo French Mr. and Mrs. Lewis L. French Mrs. Dawn Frevert Mr. Joseph Friedland Ms. Elly Friedman Mr. and Mrs. Phillip Friedman Ms. Ruth Friedman Mr. and Mrs. H. B. Friedrich Mr. J. G. Frierson Mr. Carl H. Fritts Ms. Elizabeth Frostad Dr. and Mrs. Paul D. Fuchs Mr. and Mrs. Samuel R. Fujimoto Mr. Jerry Fulenwider Mr. William H. Fullmer Mr. and Mrs. Carl E. Fulton Mr. Michael Furay Mr. and Mrs. Gary Furness Gabel, Cook & Associates, Inc. Major General and Mrs. Evan R. Gaddis Ms. Marion Galison Ms. Susan Gallagher Ms. Margaret Gallagher Thompson Dr. David Gandler Ms. Marcia Garatt Ms. Hannah Gardner and Mr. Patrick O'Donnell Mrs. Lorraine Gardner Mr. Robert Gardner Ms. Dorothy B. Garner Ms. Linda Garnett Mr. and Mrs. George P. Garrett Ms. Jennifer Garrigues Mr. Paul Garvey Mr. and Mrs. Gary Gassel Mr. and Mrs. Richard Gassner Ms. Catherine T. Gately Mrs. Mary J. Gates Mr. and Mrs. William E. Gates Mr. John M. Gauker Mr. Philip Geier Ms. Saskia H. Geisel Mr. and Mrs. Sidney C. Gelb Mr. and Mrs. Fred Geldon Aaron S. Geller, M.D. General Dairy Manufacturing Co. Tony P. George, M.D. Ms. Margaret Georgoulis Mr. and Mrs. Angus M. Gephart Mr. John Gephart Mr. and Mrs. Joseph Germano Theodore F. & Josephine Gerson Philanthropic Fund Ms. Carla Getto Mr. and Mrs. Anthony Giambalvo Ms. Maria Gianfrancisco Mr. Donald Giddon Mr. and Mrs. George Giffen Ms. Patricia R. Gilbert Mr. Keith Gilbertson Mr. David Gilboe Mr. and Mrs. Thomas Gilroy Dr. Elizabeth M. Gingerich Mr. and Mrs. Michael B. Ginsberg Dr. and Mrs. Sanjeevi Giridhar Mr. and Mrs. Ted S. Gladstone Mr. Jeffrey Glass Ms. Leslie G. Glass Ms. Nancy Glass Dr. and Mrs. Alexander H. Glassman Mr. and Mrs. Edward M. Glickman Global Impact Ms. Pamela Godfrey Ms. Barbara Godt Ms. Barbara Goebel Mr. and Mrs. Philip Goelet Mr. and Mrs. R.L.Goetzenberger, Jr. Mr. Donald Goff and Ms. Bonnie Y. Ohye Mrs. Elizabeth J. Goforth Mr. and Mrs. Michael S. Gold Mr. and Mrs. Homer Goldberg Mr. and Mrs. Alfred Golden Mr. Michael Golden Mr. and Mrs. Larry Goldenberg S. J. Goldhaber, M.D. Ms. Gerri Goldman Ms. Marilyn Goldman Mr. and Mrs. Richard Goldman Mr. and Mrs. Richard S. Goldman Ms. Susan Goldman and Ms. Ruth Edelman Goldman, Sachs & Co. Mr. and Mrs. Ira Goldreyer Mr. Peter Goldscheider Mr. and Mrs. Akiva Goldsman Mr. and Mrs. Peter B. Goldsmith Ms. Sara Goldsmith Mr. and Mrs. David Goldstein Mr. and Mrs. Gerald Goldstein Mr. Raymond T. Gonzalez Mr. and Mrs. Bernard Goodman Mr. and Mrs. Edward Goodman Mr. Bobby Goodnough Mr. and Mrs. Edward Gordon Ms. Michelle Gordon Jack and Lauren Gorman Gorter Family Foundation Gracie See Pizzeria Dr. John M. Graham Mr. and Mrs. Richard W. Graham Ms. Leslie Granoff Mr. and Mrs. John F. Grant Mr. Chester H. Graves Mr. and Mrs. Arthur M. Gray Mr. Leo J. Gray Mrs. Linda Gray-Moin Mr. and Mrs. Janis Graziano Ms. Dorothy Green Mr. Jay Green Mr. Larry Green Mr. and Mrs. Robert Green Mr. and Mrs. Jonathon M. Greenberg Mrs. Erna S. Greene Mr. and Mrs. Howard Greene Mr. Harry P. Greenwald and Ms. Babette E. Krolik Ms. Nancy Greenwood Mrs. Sherry Grenz Mr. and Mrs. Donald K. Grierson Mr. Brent Griffin Ms. Lynn Griffin Dr. Robert J. Griffin Mr. and Mrs. Roger Griffin Mr. and Mrs. Ted N. Griffin Ms. Gail Griffith Mr. and Mrs. Gordon Griggs Mr. Thomas Grimes Mr. and Mrs. Limond Grindstaff Ms. Nina Griswold Ms. Bernadette Gross Mr. and Mrs. Stan Gross Ms. Beth Grossbard Mr. and Mrs. Adam Grosser Mr. and Mrs. Michael Grossfeld Ms. Arnis Grundberg Mr. and Mrs. Harry L. Gubbins Mr. Joseph Gugliandolo Mr. and Mrs. Don R. Gummow Mrs. and Mr. Natalie R. Gundrum Mrs. Charlotte Gunn Mr. and Mrs. Jordan D. Gushurst Mr. and Mrs. Arnold Gussin Mr. Dennis Gustafson Mr. and Mrs. Nels R. Gustafson Ms. Carrie Sue Heinen and Mr. Thure O. Gustafson Mr. and Mrs. Gary D. Guzzardo Ms. Gay Gwinner Mr. and Mrs. Colin Gyles Mr. and Mrs. Paul F. Gysan Mr. and Mrs. William Hacker Mrs. Alice Hackworth Mrs. Rebecca S. Hadden Mr. and Mrs. Kenneth G. Hagen Mr. Philip Hagler Dr. and Mrs. William H. Hague Ms. Virgina Hall Ms. Glennis Halterman Ms. Victoria Ham Ms. Margaret H. Hamer Ms. Tiffany Hamill Mr. and Mrs. Donald Hamm Meyer & Raena Hammerman Foundation Mrs. Goldie Hamond Hamovit Family Philanthrophic Fund Dr. and Mrs. Max Handel Mr. and Mrs. John F. Hanley Ms. Julia Hansen Ms. Renee C. Hansen Mr. and Mrs. W.W. Hansen Mr. Tim Harlan Mrs. Jennifer Harmon Dr. and Mrs. William H. Harmon, Jr. Ms. Lorine L. Harr Mr. and Mrs. Bryant Harrell Ms. Margaret Harrell Mr. and Mrs. Peter Harriott Ms. Benilde Harris Mrs. Claudine Harris Mrs. Harriet Harris Ms. Martha Harrison Ms. Theresa A. Harrison Mr. William D. Harrison Dr. Daniel C. Hartnett Familiy Foundation Mr. Jack B. Hartog Ms. Mary Hartwig Ms. Tana L. Harvey Mr. Michael W. Haser Mr. and Mrs. Harold C. Hastings Donald N. Haupt, M.D. Mr. and Mrs. Edmund S. Hawley Mr. Herb Hayes Mr. and Mrs. Joseph Hayes Ms. Gwen T. Head Mr. and Mrs. David E. Heafield Mr. and Mrs. John Heald Healthcare Materials Management Mr. and Mrs. Lowell Heap Mrs. Janet B. Hearon-Albers Ms. Audrey B. Heckler Mr. Gary G. Heffernan Mr. and Mrs. Jacob Heffner Dr. and Mrs. Stephen I. Hegedus Mr. and Mrs. Don A. Hehner Mr. Hakon Heimer Ms. Audrey Heimler Ms. Jeanne Hein Ms. Phyllis Heischuber Mr. and Mrs. William H. Heisler, III Mr. Gerald Heller Mr. Charles A. Henderson Ms. Debra Henderson Ms. Betty H. Hendry Ms. June Henebury Mr. and Mrs. Oliver C. Henkel Mr. Herbert Henze Heritage, Steel & Slitting Co., Inc. Mr. and Mrs. Henry L. Herman Dr. Carol K. Hermann Dr. and Mrs. Howard T. Hermann Mrs. Marie C. Hermann James B. Herrmann Memorial Fund Mr. John Hess Ms. Barbara A. Heys Mr. and Mrs. Robert Hieronymus Ms. Andrea S. Higgins Mr. Jospeh Higgins Mr. Don Highland Ms. Rosalyn Hilbert Mr. and Mrs. Herbert Hild Ms. Helen M. Hill Mr. and Mrs. Raymond F. Hilliard Mr. Malvin J. Hillman Ms. Saralee G. Hillman Mr. and Mrs. Leonard A. Hillmann Ms. Linda L. Hills Ms. Kathy Hilton.

We have developed a systematic thin-layer chromatographic TLC ; technique for detecting and identifying drugs and drug metabolites on 10-cm-long silica-gel plates with organic binder fluorescent indicator a computer program SPOT CHEK ; assists in matching the data from a particular chromatogram with those obtained for known drugs recovered from serum, urine, or other specimens. The plates are developed in a single mobile phase. Visualization and detection reagents used to characterize unknowns include fluorescamine, ferric chloride perchloric acid nitric acid, Dragendorff, Marquis, Mandelin, and iodinated Dragendorff solutions, 254 nm ultraviolet light, and vapor from chlorine or hydrochloric acid. Detection limits of 5200 ng per sample spot were obtained for drugs in the database. The computer program database is based on nine reaction responses plus the plate zone locations for 243 drug substances but requires entry of only one TLC property to generate a matching list. We ran the program with an IBM-compatible 386 486 PC using an MS-DOS operating system version 6.2.

Nominees who are not granted the award in the year of nomination will be automatically included among the nominees in the two subsequent years unless the sponsors express otherwise. Sponsors will be invited to update previously submitted information. Award and Presentations: The award will be in the form of a plaque or other suitable memento. Presentation of the award will be made at the President's Reception during the Annual Meeting and infliximab.

The Basle company is also the owner of a further six patents, and is the applicant for two more, for different processes in the manufacture of diazepam. In addition 13 further processes are known to have been developed by others in East Germany, Switzerland, Canada, Denmark, France, Hungary, Sweden and Japan. These processes are of significance in countries which do not permit the patenting of pharmaceutical substances as such. Thus Dumex of Copenhagen manufactures diazepam under its own process and sells it in competition with the Roche Group in Denmark and elsewhere. There are also producers in Italy where there is no patent protection for drugs. Roche Products says that the Group is in fact faced with many hundreds of copiers throughout the world. 49. Between 1964 and 1971 nine requests for voluntary licences relating to the reference drugs have been made to Roche Products in the United Kingdom seven for operation in the United Kingdom ; but none has been granted. Roche Products states that all these requests, with perhaps the exception of those from Berk Pharmaceuticals, were from small domestic firms without resources for research or for providing medical information either nationally or internationally. The Roche Group considers that the degree and intensity of competitive research would be diminished if voluntary licensing of this kind in respect of already established drugs were to become a common practice, and it does not in general grant such licences. In this matter it argues that its views are substantially similar to those of the Banks Committee on patents in respect of compulsory licences. 50. On the other hand the Roche Group would not necessarily have similar objections in principle to the grant of licences for any active ingredient which it may have patented but which has not been generally accepted or resulted in an established market for the drug. Roche Products states that requests for voluntary licences of this kind would be highly unlikely from any small domestic firm. And further that no application of such a firm to obtain such a compulsory licence has yet been made. 15.